Developer docs
API playgroundTry for free, no card

Search company profiles

SELLAS Life Sciences

Full company profile

uuid00058e6

Namestring
SELLAS Life Sciences
Legal namestring
SELLAS Life Sciences Group, Inc.
Company typeenum
Public
Founded yearint
2006
Descriptiontext

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company headquartered at 7 Times Square in New York City, listed on NASDAQ under the ticker SLS. The company develops novel therapeutics for a broad range of cancer indications, with a pipeline built around two core clinical-stage candidates: galinpepimut-S (GPS), a multi-peptide cancer immunotherapeutic that targets the Wilms tumor 1 (WT1) protein using AI-designed heteroclitic peptides, and SLS009 (tambiciclib), a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor that induces apoptosis via MCL-1 and c-MYC suppression. GPS is licensed globally from Memorial Sloan Kettering Cancer Center, and SLS009 is licensed from GenFleet Therapeutics for territories outside Greater China. A third asset, GPS+ (nelipepimut-S), sits at the preclinical stage.

The company is pre-revenue and operates a traditional biotech go-to-market model centered on clinical development, regulatory engagement (GPS has received FDA Fast Track Designation for AML in CR2), and partnership-based commercialization. The lead program GPS is being evaluated in the Phase 3 REGAL trial in acute myeloid leukemia, which reached 78 of 80 required events as of May 11, 2026, positioning the company for a near-term pivotal readout. SLS009 is advancing through Phase 2 development in relapsed/refractory and first-line AML. Geographic commercialization rights are largely externalized through licensing agreements — 3D Medicines holds Greater China rights to GPS and GPS+, while SELLAS retains rights in all other territories — creating an asset-light path to international reach. The company is led by founder, President and CEO Angelos M. Stergiou, MD, with a management team spanning clinical development, regulatory affairs, finance, and commercial functions. With $107.1 million in cash as of March 31, 2026, plus additional Q2 2026 warrant proceeds, and a market valuation exceeding $1.5 billion as of May 2026, SELLAS is capitalized to advance its pipeline through the Phase 3 readout and into potential commercial launch.

Short descriptiontext

SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing novel cancer therapies, principally GPS (a WT1-targeting immunotherapeutic licensed from MSKCC) and SLS009 (a CDK9 inhibitor licensed from GenFleet). The company serves oncology patients with hematologic malignancies and solid tumors and is approaching a pivotal Phase 3 readout in AML.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, clinical biopharmaceuticals, CDK9 inhibitor, WT1 targeted therapy, hematologic oncology
Industry3 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage oncology biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Revenue (Future)
TypeOne Time License
Description

SELLAS is a pre-revenue clinical-stage biopharmaceutical company with no commercialized products. The company is focused on developing novel cancer therapies through clinical trials toward regulatory approval. Revenue will be generated from product sales upon successful commercialization of GPS, SLS009, or other pipeline candidates.

sellaslifesciences.com
2Licensing Revenue
TypeLicensing Royalties
Description

The company has entered into licensing agreements that may generate future milestone payments and royalties. This includes licensing agreements with 3D Medicines for Greater China territory and retention of rights outside Greater China for GPS and GPS+, and licensing arrangements for SLS009 outside Greater China with GenFleet Therapeutics.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SELLAS is a late-stage clinical biopharmaceutical company that develops novel cancer therapeutics. Its core product candidates are galinpepimut-S (GPS), a WT1-targeting multi-peptide cancer immunotherapeutic licensed from Memorial Sloan Kettering Cancer Center, and SLS009, a highly selective small-molecule CDK9 inhibitor licensed from GenFleet Therapeutics. The pipeline additionally includes GPS+, a next-generation heptavalent WT1 immunotherapeutic currently at the preclinical stage.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Median OS of 21 months for GPS vs 5.4 months for standard care in AML CR2 patients (p<0.02)
+4 more records
Product overview1 text field

SELLAS Life Sciences is a late-stage clinical biopharmaceutical company focused on novel cancer therapies. The company's product portfolio consists of two core clinical-stage candidates: Galinpepimut-S (GPS), a WT1-targeting cancer immunotherapeutic that activates T-cell immune responses against WT1-positive cancer cells, and SLS009, a highly selective CDK9 inhibitor that induces cancer cell apoptosis through MCL-1 and MYC suppression. Additionally, GPS+ represents a next-generation heptavalent immunotherapeutic in preclinical development. GPS is licensed globally from Memorial Sloan Kettering Cancer Center, while SLS009 is licensed from GenFleet Therapeutics for territories outside Greater China.

Product and service3 records
1Galinpepimut-S (GPS)
CategoryWT1 cancer immunotherapy (investigational)
Description

A multi-peptide cancer immunotherapeutic targeting the Wilms Tumor 1 (WT1) protein. It contains four heteroclitic peptides (two with single amino acid mutations designed using artificial intelligence) that activate CD4 and CD8 T-cell responses against WT1-expressing cancer cells while sparing normal cells. Designed for use as maintenance therapy to prevent relapse in patients with WT1-positive hematologic malignancies and solid tumors, including acute myeloid leukemia (AML), multiple myeloma, malignant pleural mesothelioma, ovarian cancer, and peripheral T-cell lymphoma.

2SLS009 (tambiciclib)
CategoryCDK9 inhibitor oncology therapy (investigational)
Description

A next-generation highly selective small-molecule cyclin-dependent kinase 9 (CDK9) inhibitor that decreases MCL-1 and c-MYC protein levels, inducing apoptosis and cell cycle arrest in cancer cells. Designed to address resistance to venetoclax-based therapies by targeting MCL-1, a dominant survival mechanism after venetoclax failure. Demonstrated enhanced potency with repeated exposure (IC50 reduced from approximately 50 nM to 20 nM) and improved specificity versus first-generation CDK9 inhibitors, with the potential for reduced toxicity. Indicated for relapsed/refractory acute myeloid leukemia and other hematologic malignancies.

3GPS+ (Nelipepimut-S)
CategoryNext-generation WT1 immunotherapy (preclinical)
Description

A next-generation heptavalent WT1-targeting immunotherapeutic designed to expand upon the GPS platform. Currently at the preclinical development stage, intended for treatment of cancers expressing the WT1 protein across multiple indications.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-01
Description

In March 2022, SELLAS entered into an exclusive license agreement with GenFleet Therapeutics for the development and commercialization of SLS009, a highly selective CDK9 inhibitor, across all therapeutic and diagnostic uses worldwide outside of the Greater China Region.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-12-01
Description

In December 2020, SELLAS entered into an exclusive license agreement with 3D Medicines Inc., a China-based biopharmaceutical company, for the development and commercialization of GPS and next-generation heptavalent immunotherapeutic GPS+ across all therapeutic and diagnostic uses in Greater China territory (mainland China, Hong Kong, Macau and Taiwan). SELLAS retained sole rights to GPS and GPS+ outside of Greater China.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2014-09-01
Description

In September 2014, SELLAS announced an exclusive global collaboration and exclusive license agreement with MSKCC for the development, marketing and commercialization of MSKCC's proprietary WT1 cancer immunotherapy, galinpepimut-S (GPS). This is SELLAS's core partnership for its lead product candidate.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Late-stage hematology-focused biopharma developing imetelstat for lower-risk MDS and AML. Comparable to SELLAS as a small-cap, late-stage oncology company with a single pivotal hematologic asset and limited commercial footprint.

TypeDirect peer
Description

Commercial and late-stage hematology/oncology company with approved hematologic assets and an active pipeline. Comparable as a small-cap public biopharma operating in hematologic malignancies with similar regulatory and commercial dynamics.

TypeDirect peer
Description

Late-stage precision oncology company developing kinase inhibitors in hematologic malignancies. Comparable to SELLAS in stage (Phase 2/3), kinase-focused mechanism (overlapping with SLS009 CDK9), and small-cap public profile.

4Syros Pharmaceuticals
TypeDirect peer
Description

Clinical-stage biopharma focused on heme malignancies, including AML and MDS, with small-molecule and gene-control approaches. Comparable in indication focus (AML/MDS), small-cap public profile, and reliance on a small set of clinical assets.

TypeDirect peer
Description

Clinical-stage oncology company developing small-molecule therapies for cancer, including hematologic malignancies. Comparable as a small-cap, late-clinical-stage public biopharma targeting oncology indications with limited commercial infrastructure.

TypeDirect peer
Description

Clinical-stage oncology company developing CDK9 and other targeted therapies in hematologic malignancies. Directly comparable to SLS009 on CDK9 mechanism and AML/ALL patient populations.

TypeBroad incumbent
Description

Large oncology biopharma with venetoclax (Venclexta) in AML — the backbone of combinations SLS009 is being tested with. Relevant as the dominant incumbent in venetoclax-based AML regimens and a potential combination or commercialization partner.

8Bristol Myers Squibb
TypeBroad incumbent
Description

Major oncology biopharma with established AML and hematology franchises (e.g., azacitidine, cytarabine combinations). Comparable as a broad incumbent operating in the same indications where SELLAS is testing its pipeline.

TypeBroad incumbent
Description

Established biopharma with a significant hematology/oncology franchise including AML therapies (e.g., Vyxeos). Comparable as a broader incumbent with overlapping AML patient populations and commercial channels.

10Astex Pharmaceuticals (Otsuka)
TypeBroad incumbent
Description

Cancer therapeutics developer and CDK inhibitor originator (with drugs like decitabine/cedazuridine and earlier CDK programs). Comparable as an established player with kinase-inhibitor expertise overlapping SLS009's CDK9 mechanism.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SELLAS Life Sciences

Clinical-stage oncology biopharmaceuticalssellaslifesciences.com

SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing novel cancer therapies, principally GPS (a WT1-targeting immunotherapeutic licensed from MSKCC) and SLS009 (a CDK9 inhibitor licensed from GenFleet). The company serves oncology patients with hematologic malignancies and solid tumors and is approaching a pivotal Phase 3 readout in AML.

What SELLAS Life Sciences does

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company headquartered at 7 Times Square in New York City, listed on NASDAQ under the ticker SLS. The company develops novel therapeutics for a broad range of cancer indications, with a pipeline built around two core clinical-stage candidates: galinpepimut-S (GPS), a multi-peptide cancer immunotherapeutic that targets the Wilms tumor 1 (WT1) protein using AI-designed heteroclitic peptides, and SLS009 (tambiciclib), a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor that induces apoptosis via MCL-1 and c-MYC suppression. GPS is licensed globally from Memorial Sloan Kettering Cancer Center, and SLS009 is licensed from GenFleet Therapeutics for territories outside Greater China. A third asset, GPS+ (nelipepimut-S), sits at the preclinical stage.

The company is pre-revenue and operates a traditional biotech go-to-market model centered on clinical development, regulatory engagement (GPS has received FDA Fast Track Designation for AML in CR2), and partnership-based commercialization. The lead program GPS is being evaluated in the Phase 3 REGAL trial in acute myeloid leukemia, which reached 78 of 80 required events as of May 11, 2026, positioning the company for a near-term pivotal readout. SLS009 is advancing through Phase 2 development in relapsed/refractory and first-line AML. Geographic commercialization rights are largely externalized through licensing agreements — 3D Medicines holds Greater China rights to GPS and GPS+, while SELLAS retains rights in all other territories — creating an asset-light path to international reach. The company is led by founder, President and CEO Angelos M. Stergiou, MD, with a management team spanning clinical development, regulatory affairs, finance, and commercial functions. With $107.1 million in cash as of March 31, 2026, plus additional Q2 2026 warrant proceeds, and a market valuation exceeding $1.5 billion as of May 2026, SELLAS is capitalized to advance its pipeline through the Phase 3 readout and into potential commercial launch.

SELLAS Life Sciences firmographics

Firmographics
Name
SELLAS Life Sciences
Legal name
SELLAS Life Sciences Group, Inc.
Website
https://sellaslifesciences.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing novel cancer therapies, principally GPS (a WT1-targeting immunotherapeutic licensed from MSKCC) and SLS009 (a CDK9 inhibitor licensed from GenFleet). The company serves oncology patients with hematologic malignancies and solid tumors and is approaching a pivotal Phase 3 readout in AML.
Ownership category
akta.pro rank

SELLAS Life Sciences industry classification

Industry
Product category
Clinical-stage oncology biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Cancer immunotherapy
  • Clinical biopharmaceuticals
  • CDK9 inhibitor
  • WT1 targeted therapy
  • Hematologic oncology

Where SELLAS Life Sciences is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

SELLAS Life Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Product Revenue (Future): SELLAS is a pre-revenue clinical-stage biopharmaceutical company with no commercialized products. The company is focused on developing novel cancer therapies through clinical trials toward regulatory approval. Revenue will be generated from product sales upon successful commercialization of GPS, SLS009, or other pipeline candidates.
  2. Licensing Revenue: The company has entered into licensing agreements that may generate future milestone payments and royalties. This includes licensing agreements with 3D Medicines for Greater China territory and retention of rights outside Greater China for GPS and GPS+, and licensing arrangements for SLS009 outside Greater China with GenFleet Therapeutics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

SELLAS Life Sciences product offering

Product offering

Core offering

SELLAS is a late-stage clinical biopharmaceutical company that develops novel cancer therapeutics. Its core product candidates are galinpepimut-S (GPS), a WT1-targeting multi-peptide cancer immunotherapeutic licensed from Memorial Sloan Kettering Cancer Center, and SLS009, a highly selective small-molecule CDK9 inhibitor licensed from GenFleet Therapeutics. The pipeline additionally includes GPS+, a next-generation heptavalent WT1 immunotherapeutic currently at the preclinical stage.

Product overview

SELLAS Life Sciences is a late-stage clinical biopharmaceutical company focused on novel cancer therapies. The company's product portfolio consists of two core clinical-stage candidates: Galinpepimut-S (GPS), a WT1-targeting cancer immunotherapeutic that activates T-cell immune responses against WT1-positive cancer cells, and SLS009, a highly selective CDK9 inhibitor that induces cancer cell apoptosis through MCL-1 and MYC suppression. Additionally, GPS+ represents a next-generation heptavalent immunotherapeutic in preclinical development. GPS is licensed globally from Memorial Sloan Kettering Cancer Center, while SLS009 is licensed from GenFleet Therapeutics for territories outside Greater China.

Differentiator

Problem solved

Functional benefit

Products and services

  • Galinpepimut-S (GPS) A multi-peptide cancer immunotherapeutic targeting the Wilms Tumor 1 (WT1) protein. It contains four heteroclitic peptides (two with single amino acid mutations designed using artificial intelligence) that activate CD4 and CD8 T-cell responses against WT1-expressing cancer cells while sparing normal cells. Designed for use as maintenance therapy to prevent relapse in patients with WT1-positive hematologic malignancies and solid tumors, including acute myeloid leukemia (AML), multiple myeloma, malignant pleural mesothelioma, ovarian cancer, and peripheral T-cell lymphoma.
  • SLS009 (tambiciclib) A next-generation highly selective small-molecule cyclin-dependent kinase 9 (CDK9) inhibitor that decreases MCL-1 and c-MYC protein levels, inducing apoptosis and cell cycle arrest in cancer cells. Designed to address resistance to venetoclax-based therapies by targeting MCL-1, a dominant survival mechanism after venetoclax failure. Demonstrated enhanced potency with repeated exposure (IC50 reduced from approximately 50 nM to 20 nM) and improved specificity versus first-generation CDK9 inhibitors, with the potential for reduced toxicity. Indicated for relapsed/refractory acute myeloid leukemia and other hematologic malignancies.
  • GPS+ (Nelipepimut-S) A next-generation heptavalent WT1-targeting immunotherapeutic designed to expand upon the GPS platform. Currently at the preclinical development stage, intended for treatment of cancers expressing the WT1 protein across multiple indications.

Quantifiable outcome

  • Median OS of 21 months for GPS vs 5.4 months for standard care in AML CR2 patients (p<0.02)
  • +4 more outcomes

Companies that use SELLAS Life Sciences

Customer profile

Segments2 records

Ideal customer profiles2 records

SELLAS Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

SELLAS Life Sciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and flagship.

  • GenFleet Therapeutics (Shanghai), Inc.coreStrategic or Co-development Partner · 1 March 2022In March 2022, SELLAS entered into an exclusive license agreement with GenFleet Therapeutics for the development and commercialization of SLS009, a highly selective CDK9 inhibitor, across all therapeutic and diagnostic uses worldwide outside of the Greater China Region.
  • 3D Medicines, Inc.coreStrategic or Co-development Partner · 1 December 2020In December 2020, SELLAS entered into an exclusive license agreement with 3D Medicines Inc., a China-based biopharmaceutical company, for the development and commercialization of GPS and next-generation heptavalent immunotherapeutic GPS+ across all therapeutic and diagnostic uses in Greater China territory (mainland China, Hong Kong, Macau and Taiwan). SELLAS retained sole rights to GPS and GPS+ outside of Greater China.
  • Memorial Sloan Kettering Cancer Center (MSKCC)flagshipStrategic or Co-development Partner · 1 September 2014In September 2014, SELLAS announced an exclusive global collaboration and exclusive license agreement with MSKCC for the development, marketing and commercialization of MSKCC's proprietary WT1 cancer immunotherapy, galinpepimut-S (GPS). This is SELLAS's core partnership for its lead product candidate.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

SELLAS Life Sciences competitors and assessment

Company assessment

Direct peers

  • Geron Corporation: Late-stage hematology-focused biopharma developing imetelstat for lower-risk MDS and AML. Comparable to SELLAS as a small-cap, late-stage oncology company with a single pivotal hematologic asset and limited commercial footprint.
  • TG Therapeutics: Commercial and late-stage hematology/oncology company with approved hematologic assets and an active pipeline. Comparable as a small-cap public biopharma operating in hematologic malignancies with similar regulatory and commercial dynamics.
  • Cogent Biosciences: Late-stage precision oncology company developing kinase inhibitors in hematologic malignancies. Comparable to SELLAS in stage (Phase 2/3), kinase-focused mechanism (overlapping with SLS009 CDK9), and small-cap public profile.
  • Syros Pharmaceuticals: Clinical-stage biopharma focused on heme malignancies, including AML and MDS, with small-molecule and gene-control approaches. Comparable in indication focus (AML/MDS), small-cap public profile, and reliance on a small set of clinical assets.
  • Aprea Therapeutics: Clinical-stage oncology company developing small-molecule therapies for cancer, including hematologic malignancies. Comparable as a small-cap, late-clinical-stage public biopharma targeting oncology indications with limited commercial infrastructure.
  • Kronos Bio: Clinical-stage oncology company developing CDK9 and other targeted therapies in hematologic malignancies. Directly comparable to SLS009 on CDK9 mechanism and AML/ALL patient populations.

Broad incumbents

  • AbbVie: Large oncology biopharma with venetoclax (Venclexta) in AML — the backbone of combinations SLS009 is being tested with. Relevant as the dominant incumbent in venetoclax-based AML regimens and a potential combination or commercialization partner.
  • Bristol Myers Squibb: Major oncology biopharma with established AML and hematology franchises (e.g., azacitidine, cytarabine combinations). Comparable as a broad incumbent operating in the same indications where SELLAS is testing its pipeline.
  • Jazz Pharmaceuticals: Established biopharma with a significant hematology/oncology franchise including AML therapies (e.g., Vyxeos). Comparable as a broader incumbent with overlapping AML patient populations and commercial channels.
  • Astex Pharmaceuticals (Otsuka): Cancer therapeutics developer and CDK inhibitor originator (with drugs like decitabine/cedazuridine and earlier CDK programs). Comparable as an established player with kinase-inhibitor expertise overlapping SLS009's CDK9 mechanism.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

SELLAS Life Sciences social profiles

Digital presence

SELLAS Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SELLAS Life Sciences leadership team

Management profile

Number of profiles

Profiles5 records

SELLAS Life Sciences funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SELLAS Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SELLAS Life Sciences

What does SELLAS Life Sciences do?

SELLAS is a late-stage clinical biopharmaceutical company that develops novel cancer therapeutics. Its core product candidates are galinpepimut-S (GPS), a WT1-targeting multi-peptide cancer immunotherapeutic licensed from Memorial Sloan Kettering Cancer Center, and SLS009, a highly selective small-molecule CDK9 inhibitor licensed from GenFleet Therapeutics. The pipeline additionally includes GPS+, a next-generation heptavalent WT1 immunotherapeutic currently at the preclinical stage.

Is SELLAS Life Sciences a public or private company?

SELLAS Life Sciences is a public company. It is classified as public and is currently operating.

When was SELLAS Life Sciences founded?

SELLAS Life Sciences was founded in 2006. It employs 11 to 50 people.

Where is SELLAS Life Sciences based?

SELLAS Life Sciences is headquartered in New York, United States, in the North America region.

How does SELLAS Life Sciences make money?

Two revenue lines are on record. Product Revenue (Future) is the primary driver. The others are licensing Revenue.

Who are SELLAS Life Sciences's main competitors?

Direct peers on record are Geron Corporation, TG Therapeutics, Cogent Biosciences, Syros Pharmaceuticals, Aprea Therapeutics and Kronos Bio. Broad incumbents are AbbVie, Bristol Myers Squibb, Jazz Pharmaceuticals and Astex Pharmaceuticals (Otsuka).

Does SELLAS Life Sciences have an API?

No public API is recorded for SELLAS Life Sciences.

What industry is SELLAS Life Sciences in?

SELLAS Life Sciences's product category is Clinical-stage oncology biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewSELLAS Life Sciences Prices $150 Million Stock Offering at $13 Per ShareSELLAS Life Sciences entered an underwriting agreement with J.P. Morgan and TD Securities for a public offering of 11,538,462 common shares at $13 per share. The company expects net proceeds of approximately $161.8 million after discounts, commissions, and estimated expenses, with the offering expected to close on or about Nov 20, 2026.StocktwitsSLS Stock Suffers Worst Rout Since January After $150M Share Sale — But Fresh Filing Has Retail Bulls Saying Sellas Has More Buyout LeverageSellas Life Sciences priced 11.54 million new shares at $13, expecting net proceeds of $140.6 million, exceeding September cash by $5.9 million. The GPS leukemia vaccine trial showed a median survival of 24 months versus 14.7 months for control. The company aims to file for FDA approval in the first half of 2027.TradingViewSLS Stock Suffers Worst Rout Since January After $150M Share Sale — But Fresh Filing Has Retail Bulls Saying Sellas Has More Buyout LeverageSellas Life Sciences priced 11.54 million new shares at $13, expecting net proceeds of $140.6 million, after its stock fell on Thursday. The GPS leukemia vaccine trial showed median survival of 24 months versus 14.7 months for control. The company plans to file for FDA approval in the first half of 2027.PropakistaniNew Blood Cancer Vaccine Reduces Death Risk By 41%A Phase 3 trial of galinpepimut-S vaccine in acute myeloid leukemia patients showed a 41% reduction in death risk, with median survival of 24 months versus 14.7 months for other treatments. The vaccine, developed at Memorial Sloan Kettering and tested by Sellas Life Sciences, is generally well tolerated, with injection-site reactions as the most common side effect. Sellas plans to seek FDA approval, with an application expected in the first half of 2027.Business & FinancialSLS Stock Plunges Overnight As Sellas' Discounted Share Offering Has Retail Bulls Crying Foul: 'Crazy Low Price'Sellas Life Sciences priced a $150 million share offering at $13, a 28% discount to Wednesday's close, causing SLS stock to fall nearly 20% overnight. The company plans to sell 11.54 million shares and aims to file for vaccine approval in the first half of 2027.The HinduSellas’ cancer vaccine extends survival in blood cancer trial, company saysSellas Life Sciences reported that its experimental vaccine galinpepimut-S helped patients with acute myeloid leukemia live longer in a late-stage trial. Patients receiving the vaccine had a median survival of 24 months versus 14.7 months for those on best available treatment. The company plans to seek FDA approval.TradingViewSLS Stock Plunges Overnight As Sellas’ Discounted Share Offering Has Retail Bulls Crying Foul: ‘Crazy Low Price’Sellas Life Sciences priced a $150 million share offering at $13, a 28% discount to Wednesday's close, causing SLS stock to fall nearly 20% overnight. The firm plans to sell 11.54 million shares, with gross proceeds potentially reaching $172.5 million if underwriters exercise their option. It aims to file for vaccine approval in the first half of 2027.The future of tradingSELLAS Life Sciences Prices $150 Million Public Offering at $13 a ShareSellas Life Sciences priced an underwritten public offering of 11,538,462 shares at $13 per share, with gross proceeds expected to total $150 million before underwriting discounts and expenses. Underwriters have a 30-day option to buy 1,730,769 additional shares at $13 each, and the offering is expected to close on November 20, 2026.MintAfter 156% surge in a day, this American firm stock rises another 5%. What's driving the biotech share rally? | Stock Market NewsSellas Life Sciences shares rose another 5% on Wednesday after a 156% surge, following positive Phase 3 trial results for its cancer vaccine. The trial met its primary endpoint, reducing death risk by 41% in AML patients. The company plans an FDA accelerated filing and a $150 million stock offering.Business & FinancialSELLAS Life Sciences Announces Pricing Of $150.0 Million Underwritten Public OfferingSELLAS Life Sciences priced a $150 million underwritten public offering, with J.P. Morgan, TD Cowen, Mizuho, and others as lead managers. The offering is made under a shelf registration statement filed with the SEC on March 20, 2026, and a final prospectus supplement will be filed.